Advertisement
Biogen Idec
Subscribe to Biogen Idec

The Lead

Donald Johns Joins Biogen Idec to Lead ALS Innovation Hub

August 26, 2014 8:06 am | News | Comments

Biogen Idec announced that Donald R. Johns, M.D., has joined the company as vice president, leading Biogen Idec’s amyotrophic lateral sclerosis (ALS) Innovation Hub (ALS iHub).             

Biogen Idec Names Adriana Karaboutis EVP, Technology And Business Solutions

August 21, 2014 3:35 pm | by Biogen Idec | News | Comments

Biogen Idec (NASDAQ: BIIB) announced the appointment of Adriana (Andi) Karaboutis as...

Biogen Idec Second Quarter 2014 Revenues Increase 40%

July 23, 2014 9:18 am | News | Comments

Biogen Idec today reported second quarter 2014 results, including revenue of $2.4 billion, a 40...

FDA Approves the First Antihemophilic Factor, Fc Fusion Protein for Patients with Hemophilia A

June 9, 2014 8:11 am | News | Comments

The U.S. Food and Drug Administration has approved Eloctate, Antihemophilic Factor (Recombinant...

View Sample

FREE Email Newsletter

Biogen Idec and Sobi to Donate 1 Billion International Units of Clotting Factor to Support Treatment of Hemophilia in Developing World

May 12, 2014 8:22 am | News | Comments

Initially, the companies have committed to donating up to 500 million IUs to the World Federation of Hemophilia over five years to support its efforts to raise the standard of care for people with hemophilia in the developing world. The remaining 5000 million IUs of clotting factor will be made available for future distribution.

Quintiles and Biogen Idec Announce Clinical Development Partnership

April 24, 2014 8:08 am | News | Comments

Quintiles, a provider of biopharmaceutical development and commercial outsourcing services, and Biogen Idec  have entered into a five-year strategic clinical development agreement. The multi-year collaboration is designed to leverage the expertise and experience from both organizations to optimize Biogen Idec’s clinical development processes.

Biogen Idec First Quarter 2014 Revenues Reach $2.1B

April 23, 2014 8:05 am | News | Comments

Biogen Idec today reported first quarter 2014 results, including revenue of $2.1 billion, a 51% increase compared to the first quarter of 2013. The revenue growth year-over-year was driven by strong TECFIDERA performance and from recording 100% of TYSABRI ® revenues following our acquisition of complete rights for the asset in the second quarter of 2013.

Advertisement

Pfizer’s Ian Read Becomes PhRMA Board Chairman; Ken Frazier, George Scangos Assume New Posts

April 14, 2014 8:02 am | News | Comments

Ian C. Read, chairman and CEO of Pfizer, Inc, was elected chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA) at the trade association’s annual meeting. Also elected were Kenneth C. Frazier, chairman, president and CEO of Merck & Co, Inc., as chairman-elect of the PhRMA Board of Directors, and George A. Scangos, Ph.D., CEO of Biogen Idec, as Board treasurer.

Biogen Idec Names SVP and Chief Strategy Officer

April 10, 2014 8:19 am | News | Comments

Biogen Idec today announced the appointment of Adam M. Koppel, M.D., Ph.D., as senior vice president and chief strategy officer, effective May 15, 2014.                 

FDA Approves Biogen Idec’s ALPROLIX™

March 31, 2014 8:21 am | News | Comments

Biogen Idec has announced that the FDA has approved ALPROLIX™ [Coagulation Factor IX (Recombinant), Fc Fusion Protein], the first recombinant, DNA derived hemophilia B therapy with prolonged circulation in the body.      

Health Canada Approves ALPROLIX™ Therapy for Hemophilia B

March 21, 2014 8:24 am | News | Comments

Biogen Idec announced that Health Canada has approved ALPROLIX ™, for the control and prevention of bleeding episodes and routine prophylaxis in adults, and children aged 12 and older, with hemophilia B.        

Eisai and Biogen Idec to Develop Alzheimer’s Disease Treatments

March 5, 2014 8:21 am | News | Comments

Eisai and Biogen Idec announced have entered into a collaboration to develop and commercialize two of Eisai’s clinical candidates for Alzheimer’s disease (AD), E2609 and BAN2401.            

Advertisement

Moody's Upgrades Biogen Idec's Credit on MS Drug Sales

February 26, 2014 3:54 pm | News | Comments

Moody's Investors Service upgraded Biogen Idec's credit rating on Wednesday, saying the biotech drugmaker should continue to report strong sales of its multiple sclerosis drugs.            

Partners in New NIH-Industry Project to Find Meds

February 4, 2014 1:43 pm | by The Associated Press | News | Comments

Ten pharmaceutical companies, seven disease-related foundations, the drug industry's main trade group and two huge federal agencies have joined together in an unusual collaboration to share information and speed up creation and approval of new drugs needed by patients.

Biogen Wins European Approval for New MS Drug

February 3, 2014 1:32 pm | News | Comments

Biogen Idec said Monday it will launch its new multiple sclerosis drug Tecfidera in Europe in the coming weeks following approval by the European Commission. The European Union regulatory agency cleared the once-a-day pill for patients with relapsing multiple sclerosis, the most common form of the immune disease in which the body attacks the brain and spinal cord.

Biogen Idec 2013 Total Revenues Increase 26 Percent to $6.9B

January 29, 2014 9:00 am | News | Comments

Biogen Idec Inc. today reported full year and fourth quarter 2013 results, including revenue of $6.9 billion, a 26% increase compared to the prior year.                

Sangamo Teams with Biogen on Hemoglobin Conditions

January 10, 2014 8:26 am | by The Associated Press | News | Comments

Sangamo BioSciences Inc. could receive more than $300 million through a collaboration with Biogen Idec over potential treatments for conditions that affect the oxygen-carrying blood component known as hemoglobin.      

Advertisement

Biogen Idec Receives Notification from FDA of PDUFA Date Extension for ALPROLIX™

December 2, 2013 8:01 am | News | Comments

Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) has extended the initial Prescription Drug User Fee Act (PDUFA) date for its review of the Biologics License Application (BLA) for ALPROLIX™, the company’s investigational long-lasting recombinant factor IX Fc fusion protein candidate for hemophilia B.

Biogen Idec Total Revenues Increased 32% to $1.8 Billion in Third Quarter

October 28, 2013 8:21 am | News | Comments

Biogen Idec Inc. today reported third quarter 2013 total revenues of $1.8 billion, an increase of 32% over the third quarter of 2012. Non-GAAP diluted EPS for the third quarter of 2013 were $2.35, an increase of 23% over the third quarter of 2012.

Isis Earns $10 Million Milestone Payment from Biogen Idec for Advancement of ISIS-DMPK Rx to Treat Myotonic Dystrophy

October 16, 2013 8:04 am | News | Comments

Isis Pharmaceuticals, Inc. announced today that it has earned a $10 million milestone payment from Biogen Idec related to the selection and advancement of ISIS-DMPKRx to treat myotonic dystrophy type I (DM1).      

FDA Strengthens Warnings for Arzerra and Rituxan

September 26, 2013 8:41 am | News | Comments

The FDA has approved changes to the prescribing information of the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab) to add new Boxed Warning information about the risk of reactivation of hepatitis B virus (HBV) infection.

Biogen Idec Becomes Named to Dow Jones Sustainability World Index

September 24, 2013 8:01 am | News | Comments

Biogen Idec has been added to the prestigious Dow Jones Sustainability World Index becoming the first and only U.S. based biotech sector firm to make the list. The company was also named to the Dow Jones Sustainability Index (DJSI) North America for the fourth consecutive year, one of only three biotech companies included.

Isis Climbs on Spinal Muscular Atrophy Drug Study

September 20, 2013 7:58 am | News | Comments

Shares of Isis Pharmaceuticals advanced yesterday after the company reported positive results from a study of a drug designed to treat spinal muscular atrophy, a rare genetic disorder. Isis said most of the children who received the largest doses of its drug ISIS-SMN continued to show improvements in muscle function up to 14 months after treatment.

Amicus Therapeutics Enters Collaboration With Biogen Idec for Parkinson's Disease

September 10, 2013 8:25 am | News | Comments

Amicus Therapeutics, a biopharmaceutical company developing therapies for rare and orphan diseases, has entered a collaboration with Biogen Idec to discover, develop and commercialize novel small molecules for the treatment of Parkinson's disease.

Biogen Idec and Isis Pharmaceuticals to Collaborate on Neurological Disorders

September 9, 2013 8:06 am | News | Comments

Biogen Idec and Isis Pharmaceuticals, Inc. today announced that the companies have entered into a broad, multi-year collaboration to leverage antisense technology to advance the treatment of neurological diseases. The agreement combines Biogen Idec's expertise in neurology with Isis' leadership in antisense technology to develop novel therapies to treat neurological disorders.

Biogen Idec Appoints New Chief Scientific Officer

May 23, 2013 8:23 am | News | Comments

Biogen Idec today announced that Spyros Artavanis-Tsakonas, Ph.D., has been named the company’s Chief Scientific Officer (CSO). Dr. Artavanis-Tsakonas had served as interim CSO while on sabbatical from Harvard Medical School. He will now continue in this role in a permanent capacity, and will also lead the company’s research strategy, capabilities and discovery platforms.

Biogen Submits New MS Drug for FDA Approval

May 21, 2013 4:11 pm | News | Comments

Biogen Idec has submitted a new injectable multiple sclerosis drug to the Food and Drug Administration for U.S. market approval. The drug, called Plegridy, is intended to treat patients with relapsing forms of multiple sclerosis, a disease of the immune system in which the body attacks the brain and spinal cord.

FDA Accepts Biogen Idec’s BLA for Long-Lasting Factor VIII Therapy for Hemophilia A

May 13, 2013 8:31 am | News | Comments

Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for the marketing approval of ELOCTATE™ (recombinant factor VIII Fc fusion protein) for the treatment of hemophilia A.

Biogen Idec Completes Purchase of Full Rights and Control of TYSABRI®

April 3, 2013 8:00 am | News | Comments

Biogen Idec has completed its purchase of Elan Corporation’s interest in TYSABRI ® (natalizumab) and has gained full strategic, commercial and decision-making rights to TYSABRI. The transaction was originally announced on February 6, 2013.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading